Skeletal muscle loss after total gastrectomy, exacerbated by adjuvant chemotherapy.

2014 ◽  
Vol 32 (3_suppl) ◽  
pp. 168-168
Author(s):  
Kazumasa Fujitani ◽  
Yusuke Yamaoka ◽  
Toshimasa Tsujinaka ◽  
Kazuyoshi Yamamoto ◽  
Motohiro Hirao ◽  
...  
Keyword(s):  
Skeletal Muscle ◽  
Adipose Tissue ◽  
Adjuvant Chemotherapy ◽  
Muscle Mass ◽  
Skeletal Muscle Mass ◽  
Significant Loss ◽  
Muscle Loss ◽  
Clinical Factors ◽  
Improved Outcomes ◽  
Skeletal Muscle Loss

168 Background: Skeletal muscle loss is associated with physical disability, nosocomial infections, postoperative complications, and decreased survival. Preventing the loss of skeletal muscle mass after gastrectomy may lead to improved outcomes. The aims of this study were to assess changes in skeletal muscle mass after total gastrectomy (TG) and to clarify the clinical factors affecting significant loss of skeletal muscle after TG. Methods: One hundred and two patients undergoing TG for primary gastric cancer underwent abdominal computed tomography (CT) before and 1 year after TG to precisely quantify postoperative changes in skeletal muscle and adipose tissue. Univariate and multivariate logistic regression analyses identified clinical factors contributing to significant loss of skeletal muscle after TG. Results: At 1 year after TG, the mass of both skeletal muscle and adipose tissue was reduced by 6.20±6.80% and 65.8±36.1% of the preoperative values, respectively, and 26 patients (25.5%) showed a significant loss of skeletal muscle of more than 10%. Adjuvant chemotherapy with S-1 for ≥6 months (hazard ratio 26.75, 95% confidence interval 3.511 to 203.9) was identified as the single independent risk factor for a significant loss of skeletal muscle. Conclusions: Skeletal muscle loss was exacerbated by extended adjuvant chemotherapy after TG. Further research should identify appropriate nutritional interventions for maintaining skeletal muscle mass and leading to improved outcomes.

scholarly journals Skeletal muscle loss was associated with the risk of diabetes in non non-alcoholic fatty liver disease Chinese male middle-aged and elderly population, the Shanghai Changfeng Study

2021 ◽  
Author(s):  
Lingyan Chen ◽  
Mingfeng Xia ◽  
Li Wu ◽  
Qian Li ◽  
Yu Hu ◽  
...  
Keyword(s):  
Skeletal Muscle ◽  
Logistic Regression ◽  
Liver Disease ◽  
Muscle Mass ◽  
Fatty Liver Disease ◽  
Skeletal Muscle Mass ◽  
Muscle Loss ◽  
Alcoholic Fatty Liver ◽  
Skeletal Muscle Loss ◽  
Alcoholic Fatty Liver Disease

Abstract Background Previous studies have presented skeletal muscle loss was associated with diabetes mellitus (DM) and non-alcoholic fatty liver disease (NAFLD). However, whether the presence of NAFLD could influence the association between skeletal muscle mass and DM was still unknown. The aim of the present study was to investigate the relationship of skeletal muscle mass with diabetes in Chinese middle-aged and older community population, and whether the association could be effected by NAFLD. Methods A cross-sectional study of 5,626 residents aged 45 and above in Changfeng community in Shanghai were conducted. Skeletal muscle mass (SMM) was detected by dual-energy X ray absorption (DXA) and calculated as ASM% [appendicular skeletal muscle mass (ASM) (kg) /body weight*100%]. Liver fat content (LFC) was measured using a quantitative ultrasound method. Multivariate logistic regression analyses were conducted to investigate the association between ASM% quartiles with DM. Results With ASM% decreasing, fasting blood glucose (FBG), 2-hour postprandial blood glucose (2hBG) and Homeostasis model assessment for insulin resistance (HOMA-IR) as well as LFC increased in both genders, and the prevalence of diabetes and NAFLD also increased. Spearman analysis showed ASM% was negatively correlated with FBG, 2hBG and LFC. Stepwise logistic regression analysis showed after multiple adjustments, ASM% quartile was negatively associated with the risk of diabetes only in male, but not in female. Subgroup analysis found the ASM% quartiles remained negatively correlated with the risk of diabetes in male non-NAFLD population, but not in NAFLD population. When stratified by LFC quartiles, the results was similar. After multivariate adjustments, low ASM% was negatively correlated with the risk of diabetes only in the first and second LFC quartile in male, and the association remained insignificant in each LFC quartile in female. Conclusions Skeletal muscle mass was negatively associated with the risk of diabetes in male population but not in female. The presence of NAFLD weakened this association. The results suggested stratified management of diabetes should be considered according to skeletal muscle mass and the presence of NAFLD.

Effects of 6 months of abiraterone acetate (AA) on muscle and adipose mass in men with metastatic castration-resistant prostate cancer (mCRPC).

2012 ◽  
Vol 30 (5_suppl) ◽  
pp. 222-222 ◽  
Author(s):  
Samuel Craig Brondfield ◽  
Vivian K. Weinberg ◽  
Kathryn M. Koepfgen ◽  
Arturo Molina ◽  
Charles J. Ryan ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Skeletal Muscle ◽  
Adipose Tissue ◽  
Muscle Mass ◽  
Skeletal Muscle Mass ◽  
Muscle Wasting ◽  
Cross Sectional Area ◽  
Sectional Area ◽  
Cross Sectional ◽  
Adipose Mass

222 Background: AA, an inhibitor of androgen biosynthesis, has been shown to prolong overall survival in patients with mCRPC who have previously been treated with chemotherapy. Androgen deprivation therapy (ADT) has been shown to result in muscle wasting in prostate cancer pts. The effects of AA on progression of muscle and fat wasting have not been characterized. We evaluated whether 6 months of AA therapy altered total skeletal muscle mass or adipose mass. Methods: 10 sequential pts who responded to AA therapy for at least 6 months and had available computed tomography (CT) scans were retrospectively selected from the phase I-II COU-AA-002 study. CT image analysis was used to quantify change from baseline in total skeletal muscle and adipose tissue after 6 months of AA treatment. Skeletal muscle and adipose tissue cross-sectional area were calculated at the L3 level using Slice-O-Matic software V4.3. Previously published regression models were used to estimate fat-free mass, fat mass and skeletal muscle mass. Paired t-tests were performed to determine the change in measurements. Results: At baseline, 7 of 10 pts were overweight or obese (body mass index [BMI] > 25 kg/m2), and none were underweight. Advanced muscle wasting (sarcopenia, previously defined as the ratio of skeletal muscle cross-sectional area at L3 level to height < 52.4 cm2/m2) was present at baseline and 6 months in 9 of 10 pts. Over 6 months of AA treatment, pts lost an average of 1.9 kg ± 1.9 kg (p = 0.13). Mean changes (kg) (±standard deviation) in total skeletal muscle mass (−0.80 ± 1.71, p = 0.18) and total non-adipose mass (−1.44 ± 3.09, p = 0.17) were not significant. A significant decrease in total adipose mass (−0.61 ± 0.84, p = 0.048) was observed. Conclusions: Sarcopenia is prevalent in pts with mCRPC. AA was not related to significantly worsening sarcopenia or overall weight loss during the first 6 months of treatment; however, this may reflect a relatively short duration of therapy and/or small sample size. A significant loss of adipose tissue was observed, which is unexpected given the known effects of ADT, which increases adipose mass. Evaluation of additional AA treated patients is ongoing.

Whole-body skeletal muscle mass is not related to glucose tolerance or insulin sensitivity in overweight and obese men and women

2008 ◽  
Vol 33 (4) ◽  
pp. 769-774 ◽  
Author(s):  
Jennifer L. Kuk ◽  
Katherine Kilpatrick ◽  
Lance E. Davidson ◽  
Robert Hudson ◽  
Robert Ross
Keyword(s):  
Skeletal Muscle ◽  
Adipose Tissue ◽  
Insulin Sensitivity ◽  
Glucose Tolerance ◽  
Muscle Mass ◽  
Visceral Adipose Tissue ◽  
Skeletal Muscle Mass ◽  
Whole Body ◽  
Men And Women ◽  
Visceral Adipose

The relationship between skeletal muscle mass, visceral adipose tissue, insulin sensitivity, and glucose tolerance was examined in 214 overweight or obese, but otherwise healthy, men (n = 98) and women (n = 116) who participated in various exercise and (or) weight-loss intervention studies. Subjects had a 75 g oral glucose tolerance test and (or) insulin sensitivity measures by a 3 h hyperinsulinemic–euglycemic clamp technique. Whole-body skeletal muscle mass and visceral adipose tissue were measured using a multi-slice magnetic resonance imaging protocol. Total body skeletal muscle mass was not associated with any measure of glucose metabolism in men or women (p > 0.10). These observations remained independent of age and total adiposity. Conversely, visceral adipose tissue was a significant predictor of various measures of glucose metabolism in both men and women with or without control for age and (or) total body fat (p < 0.05). Although skeletal muscle is a primary site for glucose uptake and deposition, these findings suggest that unlike visceral adipose tissue, whole-body skeletal muscle mass per se is not associated with either glucose tolerance or insulin sensitivity in overweight and obese men and women.

scholarly journals Prevalence of Sarcopenia in Idiopathic Dropped Head Syndrome Patients is Similar to Healthy Volunteers

2021 ◽  
Author(s):  
Tatsuya Igawa ◽  
Norihiro Isogai ◽  
Akifumi Suzuki ◽  
Masahiro Ishizaka ◽  
Haruki Funao ◽  
...  
Keyword(s):  
Skeletal Muscle ◽  
Muscle Mass ◽  
Skeletal Muscle Mass ◽  
Significant Loss ◽  
Trunk Muscle ◽  
Healthy Individuals ◽  
Healthy Elderly ◽  
Dropped Head Syndrome ◽  
Increased Risk ◽  
Appendicular Muscle Mass

Abstract Dropped head syndrome (DHS) exhibits cervical deformity due to weakness of the cervical extensor group, and sarcopenia is characterized by progressive and systemic reduction in skeletal muscle mass. These clinical finding are associated with reduced activity of daily living, reduced quality of life, and increased risk of mortality. We collected and reviewed prospective registry data for 16 consecutive female patients with idiopathic DHS and 32 healthy individuals who matched their gender and age. The prevalence of sarcopenia and body composition data were compared. There were no differences in the prevalence of sarcopenia, appendicular muscle mass, and leg muscle mass between DHS patients and the healthy elderly. Trunk muscle mass in DHS patients was significantly lower than that in healthy individuals. A significant correlation was found between appendicular muscle mass and trunk muscle mass in healthy subjects but not in DHS patients. Sarcopenia was not associated with the onset of idiopathic DHS. The prevalence of sarcopenia was not high in patients with idiopathic DHS due to the preservation of their appendicular skeletal muscle mass. Patients with DHS were characterized by a significant loss of trunk muscle mass that may be related to the disease but not aging.

scholarly journals Assessment of adult malnutrition with bioelectrical impedance analysis

2018 ◽  
Author(s):  
Corinna Geisler ◽  
Mark Hübers ◽  
Manfred Müller
Keyword(s):  
Skeletal Muscle ◽  
Body Composition ◽  
Adipose Tissue ◽  
Muscle Mass ◽  
Bioelectrical Impedance Analysis ◽  
Skeletal Muscle Mass ◽  
Bioelectrical Impedance ◽  
Impedance Analysis ◽  
Composition Characteristics

The two aims of this study were to evaluate (i) the prevalence of malnutrition based on age, sex and BMI specific PA and (ii) to determinate what specific body composition characteristics (skeletal muscle mass and adipose tissue) are related to a low PA.

scholarly journals Mesenchymal Stem Cell-Derived Exosomes Protect Muscle Loss by miR-145-5p Activity Targeting Activin A Receptors

Cells ◽  
2021 ◽  
Vol 10 (8) ◽  
pp. 2169
Author(s):  
Kyung-Ah Cho ◽  
Da-Won Choi ◽  
Yu-Hee Kim ◽  
Jungwoo Kim ◽  
Kyung-Ha Ryu ◽  
...  
Keyword(s):  
Skeletal Muscle ◽  
Body Weight ◽  
Muscle Mass ◽  
Skeletal Muscle Mass ◽  
Total Body Weight ◽  
Activin A ◽  
Dependent Manner ◽  
Muscle Loss ◽  
Total Body

Skeletal muscle mass is decreased under a wide range of pathologic conditions. In particular, chemotherapy is well known for inducing muscle loss and atrophy. Previous studies using tonsil-derived mesenchymal stem cells (T-MSCs) or a T-MSC-conditioned medium showed effective recovery of total body weight in the chemotherapy-preconditioned bone marrow transplantation mouse model. This study investigated whether extracellular vesicles of T-MSCs, such as exosomes, are a key player in the recovery of body weight and skeletal muscle mass in chemotherapy-treated mice. T-MSC exosomes transplantation significantly decreased loss of total body weight and muscle mass in the busulfan-cyclophosphamide conditioning regimen in BALB/c recipient mice containing elevated serum activin A. Additionally, T-MSC exosomes rescued impaired C2C12 cell differentiation in the presence of activin A in vitro. We found that T-MSC exosomes possess abundant miR-145-5p, which targets activin A receptors, ACVR2A, and ACVR1B. Indeed, T-MSC exosomes rescue muscle atrophy both in vivo and in vitro via miR-145-5p dependent manner. These results suggest that T-MSC exosomes have therapeutic potential to maintain or improve skeletal muscle mass in various activin A elevated pathologic conditions.

Effects of 6 months of abiraterone acetate (AA) on muscle and adipose mass in men with metastatic castration-resistant prostate cancer (mCRPC).

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e15137-e15137
Author(s):  
Samuel Craig Brondfield ◽  
Vivian K. Weinberg ◽  
Kathryn M. Koepfgen ◽  
Arturo Molina ◽  
Charles J. Ryan ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Skeletal Muscle ◽  
Adipose Tissue ◽  
Muscle Mass ◽  
Skeletal Muscle Mass ◽  
Muscle Wasting ◽  
Cross Sectional Area ◽  
Sectional Area ◽  
Cross Sectional ◽  
Adipose Mass

e15137 Background: AA, an inhibitor of androgen biosynthesis, has been shown to prolong overall survival in patients with mCRPC who have previously been treated with chemotherapy. ADT has been shown to result in muscle wasting in prostate cancer patients. The effects of AA on progression of muscle and fat wasting have not been characterized. We evaluated whether 6 months of AA therapy altered total skeletal muscle mass or adipose mass. Methods: 10 sequential patients who responded to AA therapy for at least 6 months and had available computed tomography (CT) scans were retrospectively selected from the phase I-II COU-AA-002 study. CT image analysis was used to quantify change from baseline in total skeletal muscle and adipose tissue after 6 months of AA treatment. Skeletal muscle and adipose tissue cross-sectional area were calculated at the L3 level using Slice-O-Matic software V4.3. Previously published regression models were used to estimate fat-free mass, fat mass and skeletal muscle mass. Paired t-tests were performed to determine the change in measurements. Results: At baseline, 7 of 10 patients were overweight or obese (body mass index [BMI] > 25 kg/m2), and none were underweight. Advanced muscle wasting (sarcopenia, previously defined as the ratio of skeletal muscle cross-sectional area at L3 level to height < 52.4 cm2/m2) was present at baseline and 6 months in 9 of 10 pts. Over 6 months of AA treatment, patients lost an average of 1.9 kg ± 3.6 kg (p = 0.13). Mean changes (kg) (±standard deviation) in total skeletal muscle mass (-0.80 ± 1.71, p = 0.18) and total non-adipose mass (-1.44 ± 3.09, p = 0.17) were not significant. A significant decrease in total adipose mass (-0.61 ± 0.84, p = 0.048) was observed. Conclusions: Sarcopenia is prevalent in patients with mCRPC. AA was not related to significantly worsening sarcopenia or overall weight loss during the first 6 months of treatment; however, this may reflect a relatively short duration of therapy and/or small sample size. A significant loss of adipose tissue was observed, which is unexpected given the known effects of ADT, which increases adipose mass. Evaluation of additional AA treated patients is ongoing.

scholarly journals eIF3f depletion impedes mouse embryonic development, reduces adult skeletal muscle mass and amplifies muscle loss during disuse

2019 ◽  
Vol 597 (12) ◽  
pp. 3107-3131 ◽  
Author(s):  
Aurélie Docquier ◽  
Laura Pavlin ◽  
Audrey Raibon ◽  
Christelle Bertrand‐Gaday ◽  
Chamroeun Sar ◽  
...  
Keyword(s):  
Skeletal Muscle ◽  
Embryonic Development ◽  
Muscle Mass ◽  
Skeletal Muscle Mass ◽  
Muscle Loss ◽  
Adult Skeletal Muscle

scholarly journals Skeletal Muscle Loss and Octogenarian Status Are Associated with S-1 Adjuvant Therapy Discontinuation and Poor Prognosis after Pancreatectomy

Cancers ◽  
2021 ◽  
Vol 13 (16) ◽  
pp. 4105
Author(s):  
Mariko Tsukagoshi ◽  
Norifumi Harimoto ◽  
Kenichiro Araki ◽  
Norio Kubo ◽  
Akira Watanabe ◽  
...  
Keyword(s):  
Skeletal Muscle ◽  
Pancreatic Cancer ◽  
Adjuvant Chemotherapy ◽  
Survival Rates ◽  
Prognostic Indicator ◽  
Muscle Loss ◽  
Therapy Discontinuation ◽  
Poor Overall Survival ◽  
Free Survival ◽  
Skeletal Muscle Loss

The efficacy and prognosis of adjuvant chemotherapy for resected pancreatic cancer remain unclear. We investigated the utility and risk factors of S-1 adjuvant chemotherapy in patients with pancreatic cancer undergoing pancreatectomy. This study comprised 80 patients, including 58 patients who received S-1 adjuvant chemotherapy. Skeletal muscle loss was defined using cutoff values of skeletal muscle mass index. In total, 16 (20%) octogenarian patients underwent pancreatectomy. Skeletal muscle loss was present in 56 (70%) patients. The entire course of S-1 adjuvant chemotherapy for 6 months was completed in 33 patients (41%). S-1 adjuvant chemotherapy <6 months was an independent prognostic indicator of poor overall survival. Patients who completed S-1 adjuvant chemotherapy exhibited significantly longer overall and relapse-free survival rates than those did not complete the chemotherapy (p <0.0001 and p = 0.0003, respectively). Being an octogenarian and skeletal muscle loss were independent variables associated with the discontinuation of S-1 adjuvant chemotherapy. Finally, the S-1 adjuvant chemotherapy rates were 6.3% (1/16) and 28.6% (16/56) in octogenarian patients and those with skeletal muscle loss, respectively. S-1 adjuvant chemotherapy completion was associated with improved prognosis in patients with pancreatic cancer. Skeletal muscle loss and octogenarian status predicted the failure of S-1 adjuvant chemotherapy completion.

Sign in / Sign up

Export Citation Format

Share Document